iNNOVATE (PCYC-1127): Phase III Study of Ibrutinib/Rituximab in Waldenström Macroglobulinemia

June 1-5, 2018; Chicago, Illinois
Planned interim analysis of phase III iNNOVATE study shows significant improvements in PFS with ibrutinib plus rituximab vs rituximab alone in patients with Waldenström macroglobulinemia.
Format: Microsoft PowerPoint (.ppt)
File Size: 196 KB
Released: June 4, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Gain key clinical insights quickly with this short slideset from CCO on the use of PI3K inhibitors in the treatment of follicular lymphoma.

John M. Burke, MD Nathan H. Fowler, MD Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: June 18, 2021

Downloadable slideset on the current treatment landscape for patients with relapsed and refractory follicular lymphoma, from Clinical Care Options (CCO)

John M. Burke, MD Released: June 17, 2021

Download these expert-selected slides on novel investigational treatments and MRD testing in AML, by Clinical Care Options (CCO)

Eunice S. Wang, MD Released: June 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue